CDER courts invitations for plant tours
This article was originally published in The Gold Sheet
CDER seeks invitations to tour pharmaceutical manufacturing sites, according to a notice in the Oct. 16 Federal Register. The center wants to continue its site tours program, which provides training and development for regulatory project management staff. The two- to three-day tours often include daily workshops with industry counterparts and are intended to foster open dialogue, not "to inspect, assess, judge, or perform a regulatory function." To volunteer, contact Beth Duvall-Miller, 301-796-0700, email@example.com
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.